The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis - a case study of pharmacotherapies for moderate to severe COPD

Cost Effectiveness and Resource Allocation

Volumn 12, Issue 1, 2014, Pages

  Thorlund, Kristian ^a,b   Zafari, Zafar ^c   Druyts, Eric ^c,d   Mills, Edward J ^a,d   Sadatsafavi, Mohsen ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bayesian analysis; Cost effectiveness; Meta analysis; Multiple treatment comparison

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; MUSCARINIC AGENT; PLACEBO; SALMETEROL; LONG ACTING DRUG;

ARTICLE; BAYES THEOREM; BAYESIAN NETWORK META ANALYSIS; BAYESIAN PAIR WISE META ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; ECONOMIC EVALUATION; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS (TOPIC); METHODOLOGY; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; UNCERTAINTY; ACCURACY; COMPARATIVE EFFECTIVENESS; DRUG COMBINATION; DRUG COST; INCIDENCE; MORTALITY; PHARMACEUTICAL CARE; QUALITY OF LIFE;

EID: 84899150855     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-12-8     Document Type: Article

References (29)

1. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011, 14(4):429-37. 10.1016/j.jval.2011.01.011, 21669367.
2. Mills EJ, Ioannidis JP, Thorlund K, Schunemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012, 308(12):1246-53. 10.1001/2012.jama.11228, 23011714.
3. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri J. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011, 14(4):417-28. 10.1016/j.jval.2011.04.002, 21669366.
4. Mills EJ, Bansback N, Ghement I, Thorlund K, Kelly S, Puhan MA, Wright J. Multiple treatment comparison meta-analyses: a step forward into complexity. Clin Epidemiol 2011, 3:193-202. 3130904, 21750628.
5. Cooper NJ, Peters J, Lai MC, Juni P, Wandel S, Palmer S, Paulden M, Conti S, Welton NJ, Abrams KR, Bujkiewicz S, Spiegelhalter D, Sutton AJ. How valuable are multiple treatment comparison methods in evidence-based health-care evaluation?. Value Health 2011, 14(2):371-80. 10.1016/j.jval.2010.09.001, 21296599.
6. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996, 15(24):2733-49. 10.1002/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0, 8981683.
7. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Syst Rev 2012, 1(1):41. 10.1186/2046-4053-1-41, 3514119, 22992327.
8. Sutton AJ, Ades AE, Cooper NJ, Abrams KR. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoecon 2008, 26(9):15.
9. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence: indirect treatment comparison in meta-analysis 2009, Ottawaa: Canadian Agencies for Drugs and Technology in Health (CADTH).
10. Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical Support Document 2 - A generalised linear modelling framework fro pairwise and network meta-analysis of randomised controlled trial 2011
11. Cooper NJ, Sutton A, Abrams KR, Turner D, Wailoo A. Comprehensive decision analytic modelling in economic evaluation: a Bayesian approach. Health Econ 2003, 13(3):24.
12. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making?. Health Econ 2006, 15(7):677-87. 10.1002/hec.1093, 16491461.
13. Mannino DM, Duist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370(9589):9.
14. Connors AF, Dawson NV, Thomas C, Harrell FE, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT Study. Respir and Crit Care Med 1996, 154(4):9.
15. Celli BR, MacNee W,. ATS/ERS Task Force Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946. 10.1183/09031936.04.00014304, 15219010, ATS/ERS Task Force.
16. Mills EJ, Druyts E, Ghement I, Puhan MA. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol 2011, 3:107-29. 3072154, 21487451.
17. Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP. Comparative efficacy of indacaterol 150 mug and 300 mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysi. Int J Chron Obstruct Pulmon Dis 2011, 6:329-44. 3119108, 21697997.
18. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' Guide to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999, 282(14):7.
19. Donaldson GC, Wedzicha JA. COPD exacerbations 1: epidemiology. Thorax 2011, 61(2):5.
20. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost-effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005, 23:19.
21. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, Crapo RO, Jensen RL, Burney PG. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD 2005, 2:7. 10.1081/COPD-200050680, 17136956.
22. Dalai AA, Shah M, D'Souza AO, Rana P. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med 2011, 105(3):7.
23. MIMS MIMS: prescription drug database and drug prescription guide. 2012, 59. http://http://mims.co.uk/, MIMS.
24. Aries E. United States Life Tables 2007, London, UK: CDC.
25. Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions. Stat Med 2009, 28(25):3049-67. 10.1002/sim.3680, 19630097.
26. The R, Core T. R: A Language and Environment for Statistical Computing 2005, Vienna, Austria: R Foundation for Statistical Computing.
27. Sadatsafavi M, Najafzadeh M, Marra C. Technical note: acceptability curves could be misleading when correlated strategies are compared. Med Decis Mak 2008, 28(3):2.
28. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008, 61(5):455-63. 10.1016/j.jclinepi.2007.06.006, 18394538.
29. Song F, Clark A, Bachmann MO, Maas J. Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons. BMC Med Res Methodol 2012, 12:138. 10.1186/1471-2288-12-138, 3524036, 22970794.